• In 2013, reduced kidney function was associated with 4% of deaths worldwide, or 2.2 million deaths.
• More than half of these deaths were cardiovascular deaths.
• Among deceased donor kidney transplant recipients, those who were >30 kg (66 pounds) heavier than the donor had a 28% higher risk of transplant failure compared with equally weighted donors and recipients.
• If the kidney was from a smaller donor of the opposite sex, the relative risk of transplant failure was further elevated to 35% for a male receiving a kidney from a female donor and 50% for a female receiving a kidney from a male donor.
Advocates from the American Society of Nephrology (ASN) and the American Association of Kidney Patients (AAKP) are meeting with Representatives, Senators, and their respective staffs today to urge Congress to continue its historic support of research funding for the National Institutes of Health (NIH) and to cosponsor and pass the Living Donor Protection Act (H.R. 1270), no-cost legislation to eliminate barriers to living donation and increase access to transplants.
• Colonoscopies are being performed more often on healthier dialysis patients than on those with more limited life expectancies; however, overall, dialysis patients are being screened at a much higher rate relative to their life expectancy than their counterparts without kidney failure.
• Sickle cell trait, a common hemoglobin variant in African Americans, was associated with a twofold higher risk of developing kidney failure requiring dialysis.
• Sickle cell trait conferred a similar degree of risk as APOL1 gene variants, which are currently the most widely recognized genetic contributors to kidney disease in blacks.
• Kidney rejection initiated by antibodies that were present before transplantation is linked with a better outcome that rejection due to antibodies that arise after transplantation.
• From 2001 to 2012, HIV+ kidney failure patients on the transplant waiting list were 28% less likely to receive a transplant compared with their HIV- counterparts.
• They were half as likely to receive a kidney from a living donor.
• During rejection of a transplanted kidney, certain immune cells transform into connective tissue cells, which produce collagen and other fibers.
• This transition, which is mediated by the TGF-/Smad3 signaling pathway, leads to scarring and decreased kidney function.
• Receiving advice on limiting salt consumption helped kidney disease patients lower their systolic blood pressure by an average of 11 mmHg.
• Limiting salt intake also reduced excess fluid retention that is common among patients with kidney disease.
• Higher degrees of linguistic isolation were linked with a lower likelihood of transitioning from inactive to active status on the kidney transplant waiting list and with incomplete transplant evaluations.
• The association of linguistic isolation appeared to be most influential among Hispanic transplant candidates.
The American Society of Nephrology (ASN) is pleased to partner with the Department of Veterans Affairs (VA) to host the upcoming Kidney Innovation Summit. The Summit will take place at the Booz Allen Hamilton Center for Innovation in Washington, DC on February 9 – 10, 2017.
American Society of Nephrology (ASN) President Eleanor D. Lederer, MD, FASN, and the Society’s leadership issued the following statement regarding the January 27, 2017, Presidential Executive Order on Immigration:
• A new study found that patients on chronic hemodialysis with depression are frequently not interested in modifying or initiating anti-depressant treatment.
Kidney specialists caring for these patients are often unwilling to modify or initiate anti-depressant therapy even when patients are willing to accept recommendations from nurses to do so
• Decreased blood levels of a protein called soluble klothos were linked with an increased likelihood of experiencing kidney function decline in a group elderly well-functioning adults.
• In a phase 3 trial of patients with chronic kidney disease, 52.1% of patients receiving oral ferric citrate experienced a significant boost in hemoglobin levels (a reflection of red blood cell counts) compared with 19.1% of patients receiving placebo.
• A treatment effect was seen as early as 1-2 weeks after the start of treatment, and the response was durable.